Health Condition 1: C01- Malignant neoplasm of base of tongue Health Condition 2: C04- Malignant neoplasm of floor of mouth Health Condition 3: C03- Malignant neoplasm of gum Health Condition 4: C00- Malignant neoplasm of lip Health Condition 5: C14- Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx Health Condition 6: C06- Malignant neoplasm of other and unspecified parts of mouth Health Condition 7: C02- Malignant neoplasm of other and unspecified parts of t
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
Datta Meghe Institute of Higher Education and Research
Eligibility
Inclusion criteria
Inclusion criteria: All cases diagnosed with oral cancer over the last three years, whose tissue blocks are available in the pathology archives of the hospital as well as who will undergo operative therapy in the next three months.
Exclusion criteria
Exclusion criteria: All cancers other than those mentioned in the inclusion criteria are excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The use of CD34 immunohistochemistry staining, compared to conventional H&E staining, should significantly improve the identification of lymphovascular emboli (LVE) in patients with oral cancer and aid in better differentiation of LVE from retraction artifacts.Timepoint: Identification of lymphovascular emboli in oral cancer using CD34 IHC vs H&E staining. Over a period of next three months, slides and blocks will be retrived from archieve and stained, examined and the results statistically evaluated | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Investigate the degree of concordance between CD34 immunohistochemistry staining and H&E staining results in identifying lymphovascular emboli, exploring instances of agreement and discrepancy. 2. Correlate the presence of lymphovascular emboli identified by CD34 staining and H&E staining with other prognostic indicators such as tumor stage, grade, perineural invasion, worst pattern of invasion (WPOI), and extra-nodal extension. Timepoint: Over a period of next 3 months | — |
Countries
India
Contacts
Public ContactDr Pratibha Dawande
Department of Pathology, DMMC, Nagpur, DMIHER (DU), Wardha.
Outcome results
None listed